Molecular mechanism of copper transport in Wilson disease.
Wilson disease is an autosomal recessive disorder of copper metabolism. The Wilson disease protein is a putative copper-transporting P-type ATPase, ATP7B, whose malfunction results in the toxic accumulation of copper in the liver and brain, causing the hepatic and/or neurological symptoms accompanying this disease. The cytosolic N-terminal domain (approximately 70 kDa) of this ATPase comprises six heavy metal-associated domains, each of which contains the conserved metal-binding motif GMTCXXC. The N-terminal domain (Wilson disease copper-binding domain [WCBD]) has been expressed, purified, and characterized using various techniques. The WCBD binds six atoms of copper in the +1 oxidation state competitively, and with a greater affinity than all other metals. The copper atom is coordinated by two cysteines in a distorted linear geometry. Copper binds the WCBD in a cooperative manner and induces secondary and tertiary conformation changes. Zinc binding to the WCBD has also been characterized by circular dichroism spectroscopy and shown to produce conformational changes that are completely different from those induced by copper. The phosphorylation/nucleotide-binding domain of ATP7B has also been expressed and characterized and shown to be capable of binding ATP but lacking ATPase activity. A peptide corresponding to the sixth transmembrane domain of ATP7B has been constructed and shown to undergo secondary conformational changes upon binding a single atom of copper. Finally, a chimeric protein consisting of the WCBD and truncated ZntA, a zinc-transporting ATPase lacking the N-terminal domain, has been constructed and analyzed for metal ion selectivity. These results suggest that the core determines the metal ion specificity of P-type ATPases, and the N-terminal metal-binding domain may play a regulatory role.
Fatemi
Negah
N
Department of Structural Biology and Biochemistry Research, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ontario M59 1X8, Canada.
Sarkar
Bibudhendra
B
D000251:Adenosine Triphosphatases / Q000494:pharmacology*; D001665:Binding Sites; D027682:Cation Transport Proteins / Q000494:pharmacology*; D003300:Copper / Q000737:chemistry / Q000493:pharmacokinetics*; D000073840:Copper-Transporting ATPases; D005786:Gene Expression Regulation; D006527:Hepatolenticular Degeneration / Q000503:physiopathology*; D006801:Humans; D007477:Ions; D010766:Phosphorylation; D011487:Protein Conformation
D027682:Cation Transport Proteins; D007477:Ions; D003300:Copper; D000251:Adenosine Triphosphatases; C109898:Zn(II)-translocating P-type ATPase; C000612464:ATP7B protein, human; D000073840:Copper-Transporting ATPases